BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

4.91
Delayed Data
As of Apr 20
 +0.07 / +1.45%
Today’s Change
3.95
Today|||52-Week Range
7.39
0.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$549.1M

Company Description

BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.

Contact Information

BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Durham North Carolina 27703-8457
P:(919) 859-1302
Investor Relations:
(919) 859-7910

Employees

Shareholders

Other institutional66.23%
Mutual fund holders28.41%
Individual stakeholders22.04%

Top Executives

Jon P. StonehousePresident, Chief Executive Officer & Director
Robert BennettVice President-Investor Relations & Operations
Thomas R. StaabCFO, Treasurer, Principal Accounting Officer & SVP
William P. SheridanChief Medical Officer & Senior Vice President
Lynne M. PowellChief Commercial Officer & Senior Vice President